Diagnostic Imaging Devices are used for the visualization of structural and functional patterns of organs or tissues. Contrast Agents include Computed Tomography (CT) Contrast Agents, Magnetic Resonance Imaging (MRI) Contrast Agents, and Ultrasound Contrast Agents (microbubbles). GlobalData uses proprietary data and analytics to provide a comprehensive report on the contrast agents devices market, including market shares of different players within Japan. Buy the latest report here.
Smarter leaders trust GlobalData
In 2023, GlobalData’s Market Model methodology determined that the leading player in the contrast agents market in Japan was Bayer followed by Bracco Imaging, GE HealthCare Technologies and Guerbet.
CT Contrast Agents are used for patients at high risk of colon cancer, for full-motion heart scans in those with a high risk of heart disease, and to image complex fractures. They can also detect infarctions, tumors, calcifications, hemorrhages, bone trauma, and acute or chronic changes in the lung parenchyma. This category includes Ionic Iodinated CT Contrast Agents, Non-ionic Iodinated CT Contrast Agents, and Barium CT Contrast Agents. MRI Contrast Agents utilize radiofrequency and a strong magnetic field to generate clear and detailed images of internal organs and tissues. They enhance the clarity of MRI images by affecting the relaxation rates of water molecules in the tissue. Ultrasound Contrast Agents (microbubbles) act as acoustic backscatterers, improving image quality through the use of various operational modes
The value of the contrast agents devices market within Japan was expected to be over $200m in 2023.
For the latest complete market share analysis of contrast agents device market in Japan, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
The medical devices pipeline data used in this article were obtained from the Medical Pipeline Products Database of GlobalData’s Medical Intelligence Center. Pipeline Products database is a comprehensive source of information on medical devices, it covers 39K products which are in development stage and intended for diagnosis, treatment, and management of diseases/conditions/symptoms directly or indirectly. The pipeline products included in the database are sourced from reliable and authenticated sources, such as company websites, SEC filings, conference presentations, analyst presentations, news releases, clinical trial registries, and grants. The information is collected by following systematic research techniques and proprietary methodology.
